Journey Medical Corp (DERM)
Official siteHEALTHCARE • DRUG MANUFACTURERS - SPECIALTY & GENERIC • NASDAQ
Market Cap: $122.24M
Last updated: Nov 17, 2026 at 4:10 PM ET
Journey Medical Corp (DERM) Statistics
Journey Medical (DERM) has a market cap of $122.24M and an enterprise value of $125.49M. Its share count is up 12.46% from a year earlier.
Total Valuation
Enterprise value is 2.66% above the market cap, as debt exceeds cash.
| Market Cap | $122.24M |
|---|---|
| Enterprise Value | $125.49M |
| Latest price (Nov 17, 2026) | $3.90 |
Key Dates
| Last Earnings Date | Nov 12, 2026 |
|---|---|
| Fiscal Year End | December |
Valuation Ratios
Sales and book value multiples are 1.6x and 3.4x. Its year-end P/S ranged from 0.5x to 3.0x from 2021 to 2025.
| P/S Ratio | 1.6x |
|---|---|
| Forward P/S | 1.7x |
| P/B Ratio | 3.4x |
| P/TBV Ratio | 14.2x |
Enterprise Valuation
Counting debt and cash, the company is valued at 43.3x EBITDA.
| EV / Sales | 1.8x |
|---|---|
| EV / EBITDA | 43.3x |
Price Statistics
The stock is down 50.57% over 52 weeks and trades 31.94% below its 50-day average.
| Beta (1Y) | 1.87 |
|---|---|
| 52-Week Change | -50.57% |
| 1-Month Change | -24.56% |
| 3-Month Change | -42.73% |
| 6-Month Change | -36.59% |
| Total Return (1Y) | -50.57% |
| Total Return (3Y CAGR) | -0.76% |
| Total Return (5Y CAGR) | -15.63% |
| Return vs SPY (1Y) | -62.50% |
| Max Drawdown (1Y) | -60.04% |
| Max Drawdown (3Y) | -63.32% |
| Sharpe Ratio (1Y) | -1.02 |
| Correlation with SPY (1Y) | 0.37 |
| 50-Day Average | $5.73 |
| 200-Day Average | $6.39 |
| 52-Week Range | $3.64 to $9.55 |
| RSI (14 Days) | 31.1 |
| Average Volume (20 Days) | 214.84K |
Financial Position
Current assets cover 1.48x current liabilities, and total debt is 0.79x shareholder equity.
| Current Ratio | 1.48x |
|---|---|
| Quick Ratio | 1.34x |
| Debt / Equity | 0.79x |
| Debt / EBITDA | 9.83x |
| Interest Coverage | -0.56x |
Returns and Efficiency
Return on invested capital is -2.78% over the last 12 months, against a 5-year average of -55.45%.
| Return on Equity (ROE) | -15.83% |
|---|---|
| Return on Assets (ROA) | -4.92% |
| Return on Invested Capital (ROIC) | -2.78% |
| Return on Capital Employed (ROCE) | -4.05% |
| ROE (5Y Average) | -81.41% |
| ROA (5Y Average) | -21.76% |
| ROIC (5Y Average) | -55.45% |
| Asset Turnover | 0.74x |
| Inventory Turnover | 2.97x |
| Receivables Turnover | 1.66x |
| Cash Conversion Cycle | 208 days |
Scores
DERM has an Altman Z-Score of 0.44, in the distress zone below 1.81, and a Piotroski F-Score of 4 of 9, in the average band of 3 to 7.
Altman Z-ScoreDistress below 1.81Safe above 2.99
Piotroski F-ScoreWeak at 2 or lessStrong at 8 or more
| Altman Z-Score | 0.44 |
|---|---|
| Altman Z Zone | Distress |
| Piotroski F-Score | 4 of 9 |
| Piotroski Strength | Average |
Income Statement
Revenue of $69.52M over the last 12 months is up 17.03% from the 12 months before.
| Revenue | $69.52M |
|---|---|
| Revenue Growth (YoY) | +17.03% |
| Gross Profit | $45.83M |
| Operating Income | -$2.01M |
| Pretax Income | -$5.09M |
| Net Income | -$5.10M |
| EBITDA | $2.60M |
| EBIT | -$2.04M |
| Reported EPS (TTM) | -$0.18 |
Trailing 12 months through Sep 30, 2026.
Balance Sheet
Shareholder equity funds 31.05% of the $103.85M in total assets.
| Cash and Equivalents | $22.32M |
|---|---|
| Total Debt | $25.58M |
| Net Debt | $3.25M |
| Net Debt Per Share | $0.12 |
| Working Capital | $25.74M |
| Shareholder Equity | $32.25M |
| Book Value Per Share | $1.15 |
| Tangible Book Value | $7.71M |
| Tangible Book Per Share | $0.27 |
| Total Assets | $103.85M |
| Total Liabilities | $71.60M |
Balance sheet as of Sep 30, 2026.
Cash Flow
| Operating Cash Flow | -$8.55M |
|---|---|
| FCF Per Share | -$0.38 |
| Depreciation and Amortization | $4.64M |
Trailing 12 months through Sep 30, 2026.
Margins
The operating margin is -2.89%, against a 5-year average of -26.56%.
| Gross Margin | 65.93% |
|---|---|
| Operating Margin | -2.89% |
| Pretax Margin | -7.32% |
| Net Margin | -7.34% |
| EBITDA Margin | 3.74% |
| EBIT Margin | -2.93% |
| Gross Margin (5Y Average) | 61.49% |
| Operating Margin (5Y Average) | -26.56% |
| Net Margin (5Y Average) | -31.88% |
Growth
Revenue fell 5.66% a year over 3 years.
| Revenue Growth (3Y CAGR) | -5.66% |
|---|---|
| Revenue Growth (5Y CAGR) | +6.79% |
| Book Value Per Share Growth (2Y CAGR) | +11.11% |
| Tangible Book Per Share Growth (2Y CAGR) | +629.21% |
Dividends and Yields
DERM does not pay a dividend.
| Buyback Yield | -5.15% |
|---|---|
| Shareholder Yield | -5.15% |
Peer Position
Against 7 similar companies, DERM has the 4th highest P/S.
P/S RatioPeer median 1.4x
ROICPeer median -38.86%
Revenue Growth (Trailing 4 Quarters, YoY)Peer median +9.42%
| P/S Ratio | 1.6x vs 1.4x median |
|---|---|
| ROIC | -2.78% vs -38.86% median |
| Revenue Growth (Trailing 4 Quarters, YoY) | +17.03% vs +9.42% median |
Analyst Forecast
Consensus estimates put revenue growth at 27.60% a year over the next 2 fiscal years.
| Revenue Growth Forecast (2Y CAGR) | +27.60% |
|---|
Price Target
Analyst price targets are part of paid GNG plans. See plans
GNG Valuation
| GNG view | Undervalued |
|---|
GNG fair value is part of GNG Pro. See plans
Frequently Asked Questions About DERM
What is DERM's market cap?
Journey Medical has a market cap of $122.24M. Its enterprise value, which adds debt and subtracts cash, is $125.49M.
How many shares of DERM are outstanding?
Journey Medical has 28.07M shares outstanding. The count is up 12.46% from a year earlier.
Does DERM pay a dividend?
No. Journey Medical does not pay a dividend.
How much debt does DERM have?
Journey Medical has $25.58M of total debt and $22.32M of cash and equivalents, a net debt position of $3.25M.
DERM pages: Overview, Charting, Earnings, Forecast, Financials, Statistics, Valuation, Competitors